Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis

Journal of Thoracic Oncology

Volumn 9, Issue 9, 2014, Pages 1324-1331

  Umemura, Shigeki ^a   Mimaki, Sachiyo ^a   Makinoshima, Hideki ^a   Tada, Satoshi ^a   Ishii, Genichiro ^a   Ohmatsu, Hironobu ^a   Niho, Seiji ^a   Yoh, Kiyotaka ^a   Matsumoto, Shingo ^a   Takahashi, Akiko ^a   Morise, Masahiro ^a   Nakamura, Yuka ^a   Ochiai, Atsushi ^a   Nagai, Kanji ^a   Iwakawa, Reika ^b   Kohno, Takashi ^b   Yokota, Jun ^b   Ohe, Yuichiro ^a   Esumi, Hiroyasu ^a   Tsuchihara, Katsuya ^a   Goto, Koichi ^a   more..

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Comprehensive; Genome; Lung cancer; PI3K AKT mTOR; Small cell

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; BUPARLISIB; CD79B ANTIGEN; CISPLATIN; DACTOLISIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MAMMALIAN TARGET OF RAPAMYCIN; NUCLEAR RECEPTOR NR4A3; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE B BETA; PROTEIN P53; TRANSCRIPTION FACTOR PAX7; DNA; MTOR PROTEIN, HUMAN; PIK3CA PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ADULT; AGED; ARTICLE; CANCER SIZE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME PHOSPHORYLATION; EXON; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENOMICS; HUMAN; HUMAN CELL; HUMAN TISSUE; JAPANESE (PEOPLE); LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; ONCOGENE MYC; POINT MUTATION; PRIORITY JOURNAL; RNA INTERFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY; FOLLOW UP; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION; SMALL CELL LUNG CARCINOMA; TUMOR CELL LINE;

ADULT; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GENOMICS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; SMALL CELL LUNG CARCINOMA; TOR SERINE-THREONINE KINASES;

EID: 84906231103     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000250     Document Type: Article

References (24)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. William WN Jr, Glisson BS. Novel strategies for the treatment of smallcell lung carcinoma. Nat Rev Clin Oncol 2011;8:611-619.
3. Govindan R, Ding L, Griffith M, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 2012;150:1121-1134.
4. Kohno T, Ichikawa H, Totoki Y, et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med 2012;18:375-377.
5. Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012;18:382-384.
6. Cancer Genome Atlas Research Network. Comprehensive genomic characterisation of squamous cell lung cancers. Nature 2012; 489: 519-525.
7. Peifer M, Fernández-Cuesta L, Sos ML, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 2012;44:1104-1110.
8. Rudin CM, Durinck S, Stawiski EW, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet 2012;44:1111-1116.
9. Pietanza MC, Ladanyi M. Bringing the genomic landscape of small-cell lung cancer into focus. Nat Genet 2012;44:1074-1075.
10. Tarhini A, Kotsakis A, Gooding W, et al. Phase II study of everolimus (RAD001) in previously treated small cell lung cancer. Clin Cancer Res 2010;16:5900-5907.
11. Pandya KJ, Dahlberg S, Hidalgo M, et al. A randomised, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensivestage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500). J Thorac Oncol 2007;2:1036-1041.
12. Voortman J, Lee JH, Killian JK, et al. Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors. Proc Natl Acad Sci U S A 2010;107: 13040-13045.
13. Wojtalla A, Fischer B, Kotelevets N, et al. Targeting the phosphoinositide 3-kinase p110-α isoform impairs cell proliferation, survival, and tumor growth in small cell lung cancer. Clin Cancer Res 2013;19:96-105.
14. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol 2011;12:R41.
15. Beroukhim R, Getz G, Nghiemphu L, et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A 2007;104:20007-20012.
16. Suzuki A, Mimaki S, Yamane Y, et al. Identification and characterization of cancer mutations in Japanese lung adenocarcinoma without sequencing of normal tissue counterparts. PLoS One 2013;8:e73484.
17. Pleasance ED, Stephens PJ, O'Meara S, et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 2010;463:184-190.
18. Arriola E, Cañadas I, Arumí M, Rojo F, Rovira A, Albanell J. Genetic changes in small cell lung carcinoma. Clin Transl Oncol 2008;10:189-197.
19. Iwakawa R, Takenaka M, Kohno T, et al. Genome-wide identification of genes with amplification and/or fusion in small cell lung cancer. Genes Chromosomes Cancer 2013;52:802-816.
20. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
21. Gadgeel SM, Wozniak A. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitorresistant non-small-cell lung cancer. Clin Lung Cancer 2013;14:322-332.
22. Ilic N, Utermark T, Widlund HR, Roberts TM. PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc Natl Acad Sci U S A 2011;108:E699-E708.
23. Brennan J, O'Connor T, Makuch RW, et al. myc family DNA amplification in 107 tumors and tumor cell lines from patients with small cell lung cancer treated with different combination chemotherapy regimens. Cancer Res 1991;51:1708-1712.
24. Sos ML, Dietlein F, Peifer M, et al. A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proc Natl Acad Sci U S A 2012;109:17034-17039.